Filter Results:
(314)
Show Results For
- All HBS Web
(314)
- People (1)
- News (126)
- Research (145)
- Multimedia (13)
- Faculty Publications (92)
Show Results For
- All HBS Web
(314)
- People (1)
- News (126)
- Research (145)
- Multimedia (13)
- Faculty Publications (92)
- 14 Apr 2021
- News
The High Cost of the Slow COVID Vaccine Rollout
- 24 Apr 2014
- News
Saving lives through new vaccine technology
Michael Schrader (MBA 2012) is on a mission to help keep millions of people around the world from dying needlessly. “Right now, 2.4 million people die every year from vaccine-preventable diseases,” says Schrader, cofounder and CEO of Vaxess Technologies. While the cost... View Details
- 16 Nov 2020
- News
Moderna Announces Promising Vaccine Trial Results
Moderna released promising news on the progress of their coronavirus vaccine this morning, noting that trials showed it to be 94.5% effective. “In this pandemic, what has been awful from a public health standpoint, an economic standpoint,... View Details
- October 2012
- Teaching Note
GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships
By: Arthur A. Daemmrich
- 29 Nov 2020
- News
COVID-19 vaccine breakthroughs: What happens now?
- 06 Apr 2021
- News
Day of 4 Million Vaccines Signals Sharp Turnaround for U.S.
- 17 Feb 2022
- News
What Can Actually Convince Vaccine Skeptics to Get Their Shots
- 15 Jun 2020
- Video
Webinar: Science, Business & Vaccine Development to Combat the Pandemic.
- Article
Where America's Vaccine Triumph Fell Short
Kominers, Scott Duke. "Where America's Vaccine Triumph Fell Short." Bloomberg Opinion (April 10, 2021).
- 02 Sep 2021
- News
I Expect COVID Vaccine Boosters to Be Mandated by Companies: Gimbel
- June 2014 (Revised May 2017)
- Teaching Note
Vision 2020: Takeda and the Vaccine Business
By: John A. Quelch
- 26 Feb 2020
- News
Alumni-Led Biotech Developing Vaccine to Combat Coronavirus
As reported in the Boston Globe, Stéphane Bancel (MBA 2000, AMP 170) and his firm Moderna Therapeutics are working with the National Institutes of Health (NIH) to develop a vaccine for coronavirus. Vials of its vaccine, the company told... View Details
- 09 Jun 2020
- Cold Call Podcast
In a Pandemic, What’s the Best Strategy for the Global Vaccine Alliance?
- Winter 2022
- Article
Distributing a Billion Vaccines: COVAX Successes, Challenges, and Opportunities
By: Eric Budish, Hannah Kettler, Scott Duke Kominers, Erik Osland, Canice Prendergast and Andrew A. Torkelson
By January 2022, the COVAX international vaccine collaboration had allocated over a billion vaccines to over 140 countries. We describe and review the allocation process chosen, which reflected both an objective of equitably distributing vaccines across the world and... View Details
Keywords: Vaccines; Pandemics; Health Care and Treatment; Health Pandemics; Distribution; Supply Chain; Equality and Inequality
Budish, Eric, Hannah Kettler, Scott Duke Kominers, Erik Osland, Canice Prendergast, and Andrew A. Torkelson. "Distributing a Billion Vaccines: COVAX Successes, Challenges, and Opportunities." Oxford Review of Economic Policy 38, no. 4 (Winter 2022): 941–974.
- 23 Sep 2021
- News
The Innovation System Behind Moderna’s Covid-19 Vaccine
- 09 Sep 2021
- News